Swedbank AB Has $148.69 Million Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Swedbank AB decreased its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 1.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 414,937 shares of the biotechnology company’s stock after selling 7,718 shares during the quarter. Swedbank AB’s holdings in United Therapeutics were worth $148,693,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of UTHR. ClariVest Asset Management LLC grew its stake in United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 42 shares during the period. USA Financial Formulas bought a new position in United Therapeutics in the 3rd quarter valued at $33,000. V Square Quantitative Management LLC bought a new position in United Therapeutics in the 2nd quarter valued at $30,000. Innealta Capital LLC bought a new position in United Therapeutics in the 2nd quarter valued at $33,000. Finally, Rise Advisors LLC bought a new position in United Therapeutics in the 1st quarter valued at $32,000. Institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $400.00 price target on shares of United Therapeutics in a research report on Thursday, August 1st. TD Cowen raised their price target on United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Oppenheimer raised their price target on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 28th. Jefferies Financial Group increased their price objective on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. Finally, UBS Group increased their price objective on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a report on Monday, July 8th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $357.17.

Insiders Place Their Bets

In other news, CFO James Edgemond sold 7,794 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $355.54, for a total transaction of $2,771,078.76. Following the completion of the sale, the chief financial officer now owns 5,344 shares in the company, valued at approximately $1,900,005.76. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other United Therapeutics news, Director Raymond Dwek sold 5,000 shares of the stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $325.35, for a total transaction of $1,626,750.00. Following the sale, the director now directly owns 1,750 shares of the company’s stock, valued at approximately $569,362.50. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James Edgemond sold 7,794 shares of the stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $355.54, for a total value of $2,771,078.76. Following the sale, the chief financial officer now directly owns 5,344 shares in the company, valued at $1,900,005.76. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 101,638 shares of company stock worth $34,431,585 over the last 90 days. Company insiders own 11.90% of the company’s stock.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR traded up $2.54 during mid-day trading on Tuesday, reaching $359.64. The stock had a trading volume of 183,057 shares, compared to its average volume of 471,103. The business’s 50 day moving average price is $347.35 and its 200 day moving average price is $305.10. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $366.08. The company has a market cap of $16.00 billion, a P/E ratio of 16.41, a price-to-earnings-growth ratio of 1.29 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The business had revenue of $714.90 million for the quarter, compared to the consensus estimate of $691.87 million. During the same period in the prior year, the company posted $5.24 EPS. The company’s quarterly revenue was up 19.8% compared to the same quarter last year. Research analysts expect that United Therapeutics Co. will post 24.71 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.